Iridian Asset Management LLC CT Cuts Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Iridian Asset Management LLC CT decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 7.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,965 shares of the medical research company's stock after selling 4,078 shares during the period. Charles River Laboratories International makes up about 2.5% of Iridian Asset Management LLC CT's portfolio, making the stock its 14th largest position. Iridian Asset Management LLC CT owned approximately 0.10% of Charles River Laboratories International worth $9,408,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock worth $736,819,000 after buying an additional 3,738,018 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock valued at $346,821,000 after purchasing an additional 509,163 shares during the last quarter. Mizuho Securities USA LLC lifted its position in shares of Charles River Laboratories International by 2,336.4% during the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company's stock valued at $19,081,000 after purchasing an additional 92,895 shares in the last quarter. Premier Fund Managers Ltd boosted its holdings in Charles River Laboratories International by 56.3% during the third quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company's stock worth $49,573,000 after purchasing an additional 90,000 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after buying an additional 85,759 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CRL. UBS Group reaffirmed a "neutral" rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. StockNews.com lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Bank of America decreased their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a report on Friday, December 13th. The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Finally, Morgan Stanley reduced their target price on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 5th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $200.79.

Charles River Laboratories International Stock Down 2.9 %

Shares of CRL stock traded down $4.60 during mid-day trading on Tuesday, reaching $155.30. 552,861 shares of the company's stock traded hands, compared to its average volume of 952,043. The company's 50-day moving average price is $179.79 and its 200-day moving average price is $192.80. The company has a market cap of $7.94 billion, a P/E ratio of 19.44, a P/E/G ratio of 6.47 and a beta of 1.37. Charles River Laboratories International, Inc. has a 12 month low of $154.01 and a 12 month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).